CLRB
CLRB clinical trials: Cellectar Biosciences, Inc.
Every trial on ClinicalTrials.gov where Cellectar Biosciences, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 18
- Trials linked
- 14
- As lead sponsor
- 4
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CLRB on the catalyst calendar · CLRB registry changes
- Primary completion Feb 2028Sponsor estimatePhase 1NCT07311993Phase 1 Study of CLR 125 in Triple Negative Breast CancerCellectar Biosciences, Inc. · Breast CancerRecruitingCLRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2027Sponsor estimatePhase 1NCT05610891Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGGCellectar Biosciences, Inc. · High-Grade GliomaActive, not recruitingCLRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2027Sponsor estimatePhase 1NCT03478462Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and SarcomasCellectar Biosciences, Inc. · Pediatric Solid TumorActive, not recruitingCLRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2032Sponsor estimatePhase 3NCT07766421Evaluation of Iopofosine I 131 vs. R-CD in WM PatientsCellectar Biosciences, Inc. · Waldenstrom MacroglobulinaemiaNot yet recruitingCLRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 22, 2026Sponsor estimatePhase 2NCT02952508Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromCellectar Biosciences, Inc. · Waldenstrom MacroglobulinemiaActive, not recruitingCLRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 9, 2020ActualPhase 1NCT02278315Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple MyelomaCellectar Biosciences, Inc. · Multiple MyelomaCompletedCLRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2010ActualPhase 2NCT01058512A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard TherapyCellectar Biosciences, Inc. · Hepatitis CCompletedCLRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2010ActualPhase 3NCT00347412Study of NOV-002 in Combination With Chemotherapy to Treat Lung CancerCellectar Biosciences, Inc. · Non Small Cell Lung CancerCompletedCLRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2015Sponsor estimatePhase 2NCT01898273Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent GlioblastomaCellectar Biosciences, Inc. · GlioblastomaTerminatedCLRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2013ActualPhase 1NCT01495663Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has ReturnedCellectar Biosciences, Inc. · CancerCompletedCLRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2008ActualPhase 2NCT00345540Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian CancerCellectar Biosciences, Inc. · Ovarian CancerCompletedCLRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2014Sponsor estimatePhase 2NCT01778088Open-Label Study of I-131-CLR1404 in Subjects With Recurrent GliomaCellectar Biosciences, Inc. · GliomaWithdrawnCLRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2010ActualPhase 1NCT00925275Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid TumorsCellectar, Inc · Solid TumorsCompletedCLRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredPhase 1NCT00372983Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard TherapyCellectar Biosciences, Inc. · Hepatitis CCompletedCLRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 19, 2022ActualPhase 1NCT04105543CLR 131 Combined With Radiation for Head and Neck CancerUniversity of Wisconsin, Madison · Head and Neck CancerCompletedCLRBCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2016ActualNo phase registeredNCT01662284Study of 124I-NM404 in Advanced Solid MalignanciesUniversity of Wisconsin, Madison · Triple Negative Breast, Prostate, Colorectal, Gastric, Ovarian, Pancreatic, Esophageal, Soft Tissue Sarcoma, and Head & Neck CancerTerminatedCLRBCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 1, 2014ActualPhase 1NCT00582283NM404 as an Imaging Agent in Patients With NSCLCUniversity of Wisconsin, Madison · Non Small Cell Lung CancerCompletedCLRBCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredPhase 2NCT00960726NOV-002 in Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer Center · LeukemiaWithdrawnCLRBCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 18 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner